Narrow search
Showing 1 - 10 of 44,479
Cover Image
Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
Bansback, Nick; Ara, Roberta; Karnon, Jonathan; Anis, Aslam - In: PharmacoEconomics 26 (2008) 5, pp. 395-408
We reviewed the clinical measures used in rheumatoid arthritis (RA) economic evaluations with respect to their relevance and sensitivity to changes in survival, health-related quality of life (HR-QOL) and costs. We compared the measures from the economic perspective and discussed the validity of...
Persistent link: https://www.econbiz.de/10005449252
Cover Image
Management of Schizophrenia: Defining the Role of Long-Acting Injectable Risperidone
Curran, Monique P.; Keating, Gillian M. - In: Disease Management and Health Outcomes 14 (2006) 2, pp. 107-125
Schizophrenia is a chronic disease that typically manifests during adolescence and early adulthood. Treatment of this disease consumes a significant proportion of the healthcare budget (billions of dollars in the US). Primary management options for schizophrenia include both pharmacologic and...
Persistent link: https://www.econbiz.de/10005404603
Cover Image
New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses
Mapel, Douglas W.; Roberts, Melissa H. - In: PharmacoEconomics 30 (2012) 10, pp. 869-885
such as Markov modelling, and they have usually found that newer therapies have favourable cost effectiveness. However, new …, known as exacerbations, and approaches to modelling the cost benefit of exacerbation reduction; (iii) quality …; (v) the limitations of Markov modelling; and (vi) the problem of outliers. …
Persistent link: https://www.econbiz.de/10010569819
Cover Image
Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation
Dunn, Christopher J.; Foster, Rachel H. - In: PharmacoEconomics 16 (1999) 6, pp. 711-741
Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...
Persistent link: https://www.econbiz.de/10005243110
Cover Image
Book Review
Adis International Limited - In: PharmacoEconomics 26 (2008) 12, pp. 1065-1065
DOI: 10.2165/0019053-200826120-00008
Persistent link: https://www.econbiz.de/10005243120
Cover Image
Prevention of Recurrent Rhinopharyngitis in At-Risk Children in France: A Cost-Effectiveness Model for a Nonspecific Immunostimulating Bacterial Extract (OM-85 BV)
Pessey, Jean-Jacques; Megas, Francoise; Arnould, Benoit; … - In: PharmacoEconomics 21 (2003) 14, pp. 1053-1068
Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The...
Persistent link: https://www.econbiz.de/10005243125
Cover Image
Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox Presented in part at the Society of General Internal Medicine 16th Annual Meeting: 1993 Apr; Washingto...
Smith, Kenneth J.; Roberts, Mark S. - In: PharmacoEconomics 13 (1998) 5, pp. 645-651
Treatment of adult chickenpox with aciclovir is controversial because of the relatively high cost of medication and small proven benefits of therapy. A decision-tree model was used to estimate the cost effectiveness of aciclovir, from third-party payer and societal perspectives: the incremental...
Persistent link: https://www.econbiz.de/10005243155
Cover Image
Cost Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
Walters, Daniel J.; Solomkin, Joseph S.; Paladino, Joseph A. - In: PharmacoEconomics 16 (1999) 5, pp. 551-561
Objective: To compare the cost effectiveness of sequential intravenous (IV) to oral ciprofloxacin plus metronidazole (CIP/MTZ IV/PO) with that of IV ciprofloxacin plus IV metronidazole (CIP/MTZ IV) and IV imipenem-cilastatin (IMI IV) in patients with intra-abdominal infections. Design and...
Persistent link: https://www.econbiz.de/10005243176
Cover Image
Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus
Maetzel, Andreas; Ruof, Jorg; Covington, Melva; Wolf, Anne - In: PharmacoEconomics 21 (2003) 7, pp. 501-512
Objective: To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard...
Persistent link: https://www.econbiz.de/10005243210
Cover Image
Pravastatin: A Pharmacoeconomic Review of its use in Primary and Secondary Prevention of Coronary Heart Disease
Coukell, Allan J.; Wilde, Michelle I. - In: PharmacoEconomics 14 (1998) 2, pp. 217-236
Coronary heart disease (CHD) is a major cause of death and illness in industrialised countries. Like other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, pravastatin reduces total and low density lipoprotein (LDL)-cholesterol levels and increases high density lipoprotein...
Persistent link: https://www.econbiz.de/10005243215